American Medical Association statement on antibody treatments

Community NewsNews
298

Translate to Spanish or other 102 languages!

We are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Image for illustration purposes.
We are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Image for illustration purposes.

Mega Doctor News

- Advertisement -

Gerald E. Harmon, M.D.
President, American Medical Association

“Given the latest data showing the Omicron variant of SARS-CoV-2 is responsible for 99% of current COVID-19 infections, we are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Limiting the use of these treatments will help ensure patients receive the best available therapy. We encourage physicians to reference the current National Institutes of Health (NIH) COVID-19 treatment guidelines for the latest information on authorized therapies and recommendations for their use.

“We continue to strongly urge every eligible individual to make sure they are up to date on their COVID-19 vaccinations, including booster doses. The Omicron variant is highly contagious and the unvaccinated remain most at risk of severe illness, hospitalization and death if infected. Data further suggests that a booster dose provides greater protection against the Omicron variant.”

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
What drives vaccine hesitancy?
Next article
Long-acting Antibody Treatment vs. Omicron Variant in Patients with Compromised Immune System

More Articles

STC Offers EKG Technician Training to Prepare Students for Careers in Healthcare

South Texas College (STC) is offering an electrocardiography (EKG) technician course through its Continuing Education and Workforce Development division, providing students with hands-on training and an opportunity to take the first step toward a career in healthcare. 

FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer  

The U.S. Food and Drug Administration expanded the approved use of Anktiva (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guérin (BCG), to include adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has not responded to BCG treatment.

Do You Want to Be an Angel? This Is Your Opportunity

Becoming an angel for someone facing cancer may be as simple as donating $3 or $5. Through DHR Health’s annual Bras for a Cause fundraiser, community members can help patients experiencing financial difficulties while supporting breast cancer awareness and early detection.

Payne Weslaco Chevrolet Salutes STHS’ ER Heroes with $1,000 Donation

When every second counts, emergency room personnel play a critical role in saving lives. From heart attacks and strokes to serious injuries caused by car crashes, falls and other emergencies, these frontline healthcare professionals are trained to act quickly when patients need them most.
- Advertisement -